secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001651308-24-000028
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves BeiGene's TEVIMBRA for ESCC after prior chemo; available H2 2024
-----------------------------------------------------------------------------

- FDA approved TEVIMBRA (tislelizumab) for ESCC after prior chemo; first US indication; available H2 2024.
- Approval based on RATIONALE 302: median OS 8.6 vs 6.3 months (HR=0.70, p=0.0001).
- FDA also reviewing BLAs for first-line ESCC (target July 2024) and G/GEJ adenocarcinoma (target Dec 2024).
- Over 900,000 patients prescribed TEVIMBRA globally; 17+ registration-enabling trials ongoing.
- Safety profile favorable over chemo; common adverse reactions include increased glucose, decreased hemoglobin, fatigue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000028/0001651308-24-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000028/bgne-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer